A pharmaceutical combination comprising (a) a B-Raf inhibitor and (b) a historic deacetylase inhibitor; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.